Jump to content

Danicopan: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Next edit →
Content deleted Content added
VisualWikitext
create
(No difference)

Revision as of 04:30, 24 February 2024

Danicopan
Clinical data
Trade namesVoydeya
Other namesACH-4471
Routes of
administration		By mouth
Drug classComplement factor D inhibitor
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • (2S,4R)-1-{2-[3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl]acetyl}-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide
CAS Number
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.398.865 Edit this at Wikidata
Chemical and physical data
FormulaC6H3BrFN7O3
Molar mass320.038 g·mol−1
3D model (JSmol)
  • CC(=O)C1=NN(CC(=O)N2C[C@H](F)C[C@H]2C(=O)NC2=CC=CC(Br)=N2)C2=C1C=C(C=C2)C1=CN=C(C)N=C1
  • InChI=1S/C26H23BrFN7O3/c1-14(36)25-19-8-16(17-10-29-15(2)30-11-17)6-7-20(19)35(33-25)13-24(37)34-12-18(28)9-21(34)26(38)32-23-5-3-4-22(27)31-23/h3-8,10-11,18,21H,9,12-13H2,1-2H3,(H,31,32,38)/t18-,21+/m1/s1
  • Key:PIBARDGJJAGJAJ-NQIIRXRSSA-N

Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria.[1] It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells.[1]

Danicopan was approved for medical use in Japan in January 2024.[2]

Society and culture

In February 2024, the Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Voydeya, intended as add-on therapy to ravulizumab or eculizumab for the treatment of residual hemolytic anemia in adults with paroxysmal nocturnal hemoglobinuria (PNH).[1] The applicant for this medicinal product is Alexion Europe.[1]

References

  1. ^ a b c d "Voydeya EPAR". European Medicines Agency. 22 February 2024. Retrieved 24 February 2024.
  2. ^ "Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy". AstraZeneca (Press release). 19 January 2024. Retrieved 24 February 2024.

Further reading

  • Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, et al. (December 2023). "Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial". The Lancet. Haematology. 10 (12): e955–e965. doi:10.1016/S2352-3026(23)00315-0. PMID 38030318.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Danicopan&oldid=1209920913"